Trofinetide
The first FDA-approved treatment for Rett syndrome, a synthetic analogue of a naturally occurring IGF-1 tripeptide fragment.
What is Trofinetide?
Trofinetide is a synthetic analogue of glycine-proline-glutamate (GPE), the N-terminal tripeptide of IGF-1 that is naturally cleaved in the brain. It is the first and only FDA-approved treatment for Rett syndrome, a rare genetic neurological disorder. Trofinetide reduces neuroinflammation and supports synaptic function.
What Trofinetide Is Investigated For
Trofinetide is investigated and FDA-approved for Rett syndrome — a rare genetic neurological disorder caused by MECP2 mutations — in patients aged 2 years and older, and is the first-ever approved disease-modifying treatment for this condition. The strongest evidence is the pivotal Phase 3 LAVENDER trial showing statistically significant improvement on caregiver-rated and clinician-rated symptom measures versus placebo at 12 weeks, supported by the LILAC and LILAC-2 open-label extension studies demonstrating sustained benefit out to 32 months. Trofinetide is a synthetic stabilized analogue of glycine-proline-glutamate (GPE), the N-terminal tripeptide of IGF-1, and acts through neuroinflammation reduction and synaptic support rather than IGF-1 receptor signaling. The honest caveats are substantial. It does not correct the underlying MECP2 mutation and is not a cure, diarrhea is the most common adverse effect (occurring in the substantial majority of treated patients and requiring active management), and the dosing is unusual in magnitude (12 g twice daily for larger patients). A fragile X syndrome Phase 2 trial produced mixed results, and off-label use for general cognitive enhancement or neuroprotection lacks supporting evidence — the molecule is a regulated rare-disease therapy, not a nootropic.
History & Discovery
Trofinetide originated in the laboratory of Peter Gluckman at the University of Auckland in the 1990s, where work on insulin-like growth factor (IGF-1) and its naturally cleaved N-terminal tripeptide glycine-proline-glutamate (GPE) suggested that GPE itself was a neuroprotective signaling fragment with biological activity distinct from IGF-1 receptor engagement. GPE is intrinsically unstable in plasma. The chemistry program that led to trofinetide focused on producing a metabolically stabilized GPE analogue — Gly-2-methyl-Pro-Glu, originally designated NNZ-2566 — that retained the neuroprotective activity of the parent tripeptide while surviving long enough in circulation to support oral dosing. The compound was developed by Neuren Pharmaceuticals (a New Zealand–Australian biotech spun out of the Auckland academic program) through preclinical and early clinical work in indications including traumatic brain injury, fragile X syndrome, and Rett syndrome. The path through TBI and fragile X did not yield approved indications. The Rett syndrome program — picked up commercially by Acadia Pharmaceuticals through a licensing agreement with Neuren in 2018 — produced positive Phase II (LAVENDER predecessor work) and pivotal Phase III LAVENDER trial results, leading to FDA approval as Daybue in March 2023 for Rett syndrome in patients aged 2 years and older. This was the first-ever approved disease-modifying treatment for Rett syndrome, a milestone in a condition where management had been entirely symptomatic for decades. Health Canada approved trofinetide in 2024. EMA review and approvals in other jurisdictions have followed or are in progress. The trofinetide story is unusual among peptides discussed on this site: it is a fully developed, FDA-approved oral peptide therapeutic with a defined indication, label, and post-marketing surveillance, rather than a research compound or a research-chemical-market product.
How It Works
Trofinetide is based on a brain-protective fragment naturally produced from IGF-1. It calms down brain inflammation and supports the connections between neurons, addressing core problems in Rett syndrome.
Trofinetide modulates neuroinflammation by normalizing microglial activation and reducing pro-inflammatory cytokine production. It supports synaptic maturation and function through modulation of the NMDA receptor and enhancement of neurotrophic signaling. As a GPE analogue, it bypasses IGF-1 receptor signaling and acts through distinct anti-inflammatory and neuroprotective pathways. It normalizes astrocyte and microglial morphology in MeCP2-deficient models.
Evidence Snapshot
Human Clinical Evidence
Strong. Phase III LAVENDER trial demonstrated significant improvement in Rett syndrome symptoms vs placebo, leading to FDA approval in 2023.
Animal / Preclinical
Strong. Multiple studies in MeCP2-deficient mouse models showing behavioral and neurological improvement.
Mechanistic Rationale
Moderate. Neuroprotective mechanisms are characterized but the full pathway is still being elucidated.
Research Gaps & Open Questions
What the current literature has not yet settled about Trofinetide:
- 01Long-term efficacy beyond the 32-month LILAC-2 extension — multi-year and lifelong outcome data is still accumulating in real-world post-marketing populations.
- 02Predictors of response — Rett syndrome has substantial phenotypic heterogeneity, and identifying which patients are most likely to benefit (and which side-effect profiles to expect) is an active area of clinical investigation.
- 03Effects on Rett syndrome mortality, seizure frequency, and other hard endpoints — pivotal trial endpoints were behavioral and communication-focused; longer-term effects on mortality and major medical complications are still being characterized.
- 04Off-label indications — the mechanistic rationale extends to fragile X syndrome (where a Phase II trial showed mixed results), other neurodevelopmental disorders, and potentially neurodegenerative disease, but no approved indication exists outside Rett syndrome.
- 05Optimal management of GI adverse effects — caregiver and clinician guidance is published, but standardized titration and supportive-care protocols continue to evolve.
- 06Pediatric data in the youngest age groups — the DAFFODIL study extended data into 2–4-year-olds, but data in the very youngest patients remains limited.
Forms & Administration
Oral solution administered twice daily. Dose based on body weight. Taken with or without food.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Trofinetide is dosed by body weight per the FDA-approved Daybue label. Typical adult dosing for patients ≥50 kg is 12 g (12,000 mg) twice daily as oral solution; pediatric dosing is scaled to weight bands as specified in the prescribing information. Detailed weight-based tables and dose-adjustment guidance are in the official US label and should be the reference for any clinical use. The doses are deliberately large (multi-gram) because trofinetide is a tripeptide-based small molecule with relatively modest oral bioavailability and the target plasma exposure for clinical effect is high.
Frequency
Twice daily — morning and evening — administered orally as a ready-to-use liquid (with a constituted-from-powder formulation also studied). Doses are typically administered at consistent times relative to meals, though food has limited effect on exposure based on Phase I food-effect studies.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Trofinetide is intended for chronic continuous use as long as it provides clinical benefit and is tolerated. The pivotal LAVENDER trial assessed 12-week treatment; the open-label extension LILAC and longer-term LILAC-2 (32-month) studies established long-term tolerability and continued benefit in many patients. There is no scheduled discontinuation; the most common reason for stopping in real-world use is gastrointestinal intolerance (severe diarrhea is the prototypical adverse effect that limits some patients).
Protocol Notes
The dosing format itself is part of the clinical story for trofinetide. Daybue is supplied as a strawberry-flavored oral solution at 200 mg/mL, which can be administered orally or via gastrostomy tube — important for the Rett syndrome population, where many patients have feeding difficulties and existing G-tubes. The large absolute dose volumes (60 mL twice daily for an adult patient) and the diarrhea adverse-effect profile have prompted real-world management algorithms (gradual titration, anti-diarrheal co-medication where appropriate, careful hydration monitoring), addressed in published guidance for caregivers and clinicians. Weight loss from GI side effects is a recognized concern requiring monitoring and dose adjustment. Renal impairment requires dose adjustment per label. Trofinetide's approved indication is Rett syndrome. Off-label discussion in other neurodevelopmental conditions (fragile X syndrome, certain forms of intellectual disability, neurodegenerative disease) reflects the underlying mechanistic interest in the molecule but is not currently supported by approved evidence.
Dosing decisions should follow the FDA-approved Daybue prescribing information and be made by a qualified clinician familiar with Rett syndrome management. The summary here is for educational orientation, not a substitute for the official label.
Timeline of Effects
Onset
Tolerability effects (notably diarrhea, vomiting) typically emerge within the first days to weeks of dosing and are generally most pronounced during the titration period. Clinical efficacy on Rett syndrome symptom domains (assessed in the LAVENDER trial via the Rett Syndrome Behaviour Questionnaire and Clinical Global Impression-Improvement) was statistically separated from placebo by the 12-week primary endpoint, with caregiver-reported behavioral and communication effects often described emerging earlier in subsets of responders.
Peak Effect
Peak benefit in the pivotal trial was assessed at 12 weeks. Open-label extension data (LILAC, LILAC-2) suggest that benefit can be sustained or further consolidated over many months in patients who tolerate continuous dosing. Pharmacokinetically, plasma trofinetide concentrations peak within 1–2 hours of an oral dose.
After Discontinuation
Trofinetide does not produce a withdrawal syndrome of the kind seen with CNS depressants or opioids. Discontinuation typically reflects loss of perceived benefit or intolerability. Gradual loss of treatment effect after stopping is consistent with a mechanism that requires ongoing exposure to maintain its anti-inflammatory and neurotrophic-signaling effects, but the decline curve has not been characterized in detail.
Common Questions
Who Trofinetide Is NOT For
- •Known hypersensitivity to trofinetide or to any component of the Daybue formulation.
- •Severe renal impairment without dose adjustment per label — pharmacokinetic modeling supports dose modification rather than absolute contraindication, but use should follow prescribing information.
- •Pregnancy and breastfeeding — limited human pregnancy data exist; the prescribing information should be consulted for current pregnancy and lactation guidance, and use during pregnancy should be a benefit-risk discussion with the prescribing clinician.
- •Inability to tolerate the gastrointestinal adverse-effect profile, particularly severe diarrhea that risks dehydration or electrolyte disturbance and is not manageable with supportive care.
- •Concurrent severe gastrointestinal disease where additional diarrhea, vomiting, or fluid loss would be poorly tolerated.
Drug & Supplement Interactions
Trofinetide has been studied for clinical drug-interaction potential in Phase I work supporting the approved label. The compound has limited cytochrome P450 interaction in vitro and limited transporter-mediated drug interactions; overall, its interaction profile is relatively quiet for a chronically administered medication. The most clinically important interaction considerations in practice are pharmacodynamic rather than pharmacokinetic. Co-administration with other agents that cause diarrhea, fluid loss, or electrolyte disturbance can compound the GI tolerability burden. Some seizure medications used in the Rett syndrome population have their own GI tolerability profiles that interact additively with trofinetide. Drugs requiring strict dose precision (e.g., warfarin, certain anticonvulsants) should be monitored if trofinetide is added or stopped, primarily as a general clinical caution rather than because of a documented interaction. Patients on multiple chronic medications — common in the Rett syndrome population — should have their full medication list reviewed by the prescribing clinician at trofinetide initiation. The official prescribing information should be the reference for current interaction guidance; this summary is orientation, not a substitute.
Safety Profile
Common Side Effects
Cautions
- • Monitor for dehydration from GI side effects
- • May require dose adjustment for weight changes
- • Only approved for Rett syndrome
What We Don't Know
Long-term effects beyond the clinical trial duration are being monitored.
Legal Status
United States
Trofinetide is FDA-approved as Daybue (oral solution, Acadia Pharmaceuticals) for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older. Approval was granted in March 2023. It is a prescription medicine with the standard FDA-recognized labeling, REMS-free distribution, and post-marketing pharmacovigilance.
International
Approved in Canada (Health Canada) for Rett syndrome. EMA review and approvals in other jurisdictions are in progress or have followed the US approval; status varies by country and should be confirmed against current regulatory listings. As a relatively new approval for a rare disease, trofinetide's commercial availability outside major regulated markets remains uneven.
Sports & Competition
Trofinetide is not on the WADA Prohibited List. The drug is not used or studied for performance-enhancement and would not be expected to be relevant to athletes outside the very narrow context of a patient with Rett syndrome.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Trofinetide cures Rett syndrome.
Reality
Trofinetide is the first approved disease-modifying treatment for Rett syndrome, and the LAVENDER trial demonstrated statistically significant improvement on caregiver-rated and clinician-rated symptom measures versus placebo. It is not a cure. Rett syndrome is caused by MECP2 mutations and trofinetide does not address that genetic basis. The clinical effect is meaningful symptomatic improvement, not reversal of the underlying disease.
Myth
Trofinetide is the same as IGF-1 or works through the IGF-1 receptor.
Reality
Trofinetide is a synthetic stabilized analogue of glycine-proline-glutamate (GPE), the N-terminal tripeptide of IGF-1 that is naturally cleaved off in vivo. GPE acts through pathways distinct from IGF-1 receptor signaling — it modulates microglial activation, normalizes astrocyte function, and reduces neuroinflammation. It is not an IGF-1 mimetic and does not engage the IGF-1 receptor.
Myth
The diarrhea side effect is rare or minor.
Reality
Diarrhea is the most common adverse effect of trofinetide, occurring in the substantial majority of treated patients in clinical trials and in real-world use. It can be severe, can lead to discontinuation, and requires active monitoring and management — particularly in a population (Rett syndrome) where dehydration risk and feeding difficulties are baseline concerns. Caregivers and clinicians need preparation for managing GI symptoms before starting therapy.
Myth
Trofinetide is approved for general cognitive enhancement, neuroprotection, or anti-aging use.
Reality
Trofinetide is approved only for Rett syndrome. Off-label use for general cognition, neuroprotection, or longevity is not supported by approved clinical evidence, is not what the molecule was developed for, and would not be reimbursed by insurance. The compound is a prescription drug for a specific rare disease, not a nootropic.
Myth
Because trofinetide is a peptide-derived drug, it shares the safety and regulatory ambiguity of research peptides like BPC-157 or semax.
Reality
Trofinetide is a fully approved FDA-regulated drug with a defined indication, an extensive Phase III evidence base, ongoing pharmacovigilance, and standard pharmaceutical-grade manufacturing. It is in a fundamentally different regulatory and evidentiary category from research-chemical or unapproved peptides discussed elsewhere on this site. The category 'peptide therapeutic' includes both approved drugs and unapproved research compounds, and the distinction is consequential.
Published Research
31 studiesA Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults
Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)
Trofinetide-Induced Enterocolitis Syndrome in a Child with Rett Syndrome
Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis
Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study
Safety Profiles of Trofinetide in Pediatric Rett Syndrome Population: A Real-World Postmarketing Pharmacovigilance Analysis
Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome
Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials
Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome
Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome
Profile of Trofinetide in the Treatment of Rett Syndrome: Design, Development and Potential Place in Therapy
Physiologically-Based Pharmacokinetic Modeling of Trofinetide in Moderate Renal Impairment for Phase 1 Clinical Study Dose Selection with Model Validation
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study
Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study
Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome
A meta-analysis of the efficacy and safety of trofinetide in patients with rett syndrome
Safety and efficacy of trofinetide in Rett syndrome: a systematic review and meta-analysis of randomized controlled trials
Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives
Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome
Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome
Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects
Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study
Trofinetide: First Approval
A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome
A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome
Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome
A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome
Population pharmacokinetics of NNZ-2566 in healthy subjects
Quick Facts
- Class
- IGF-1 Tripeptide Analogue
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 31PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.